Other Events ·
Arcus presents casdatifan data showing 14.5-month median PFS in second-line ccRCC
RCUSArcus Biosciences, Inc.
On October 20, 2026, Arcus Biosciences presented new clinical data from its ARC-20 platform study evaluating casdatifan for clear cell renal cell carcinoma (ccRCC). In the second-line setting, casdatifan combined with cabozantinib demonstrated a median progression-free survival of 14.5 months and an 18-month overall survival rate of 77%. First-line TKI-free combinations showed high landmark PFS rates, while late-line monotherapy yielded a median overall survival of 35 months. The company operates in the biopharmaceutical industry, developing targeted cancer therapies.